Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | GLA | P06280 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | PPARA | Q07869 | 14/20 | 0.66 |
| ▸ | PPARG | P37231 | 6/20 | 0.64 |
| ▸ | PPARD | Q03181 | 5/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15686647 | 0.86 | HPGD (0.81) | HPGDTP53GLAPOLBMAPT | |
| SCHEMBL15686112 | 0.85 | HPGD (0.83) | HPGDTP53GLAPOLBMAPT | |
| SCHEMBL27604453 | 0.84 | HPGD (1.00) | HPGDTP53GLAPOLBPPARA | |
| SCHEMBL5974498 | 0.83 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL19013993 | 0.82 | HPGD (0.78) | HPGDTP53GLAPOLBPPARA | |
| SCHEMBL21816959 | 0.82 | HPGD (0.78) | HPGDTP53GLAPOLBMAPT | |
| SCHEMBL5974323 | 0.82 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5974875 | 0.82 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL2089153 | 0.82 | PPARA (0.69) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5974097 | 0.82 | PPARA (0.80) | PPARAPPARGPPARDPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| CN-118496217-A | Inhibitors of alpha-amino-beta-carboxyhexadienoic acid semialdehyde decarboxylase | TES制药有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| EP-2480547-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | Panmira Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | HPGD 1016/4885TP53 4238/4885GLA 1642/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | HPGD 1016/4885TP53 4238/4885GLA 1642/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | HPGD 1016/4885TP53 4238/4885GLA 1642/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | HPGD 1016/4885TP53 4238/4885GLA 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.